ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0140

Therapeutic Management and Clinical Remission in a Specialized Dermatological-Rheumatological Center for Patients with Psoriasis and Psoriatic Arthritis

Jana Ziob1, Charlotte Behning1, Peter Brossart2, Thomas Bieber1, Dagmar Wilsmann-Theis3 and Valentin Schäfer4, 1University Hospital Bonn, Bonn, Germany, 2Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany, 3Department for Dermatology and Allery, University Hospital Bonn, Bonn, Germany, 4Clinic of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany

Meeting: ACR Convergence 2021

Keywords: clinical remission, psoriasis, Psoriatic arthritis, therapeutic management

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: An interdisciplinary approach involving dermatologists and rheumatologists is required for the management of patients with psoriatic arthritis (PsA). The purpose of our study was to examine dermatological-rheumatological therapeutic management of patients with psoriasis and PsA.

Methods: A retrospective cohort analysis was performed of all dermatology-rheumatology consultations from April 1st, 2016 to January 31st, 2020. From March 1st, 2018 a specialized interdisciplinary PsA center was established. Clinical data including baseline characteristics, treatment status and treatment outcome were collected and analyzed. A follow-up was performed until January 27th, 2021.

Results: A total of 404 consultations were studied, including 218 psoriasis patients and 103 PsA patients. 34.4 percent of psoriasis patients and 69.9 percent of PsA patients switched systemic medication following consultation. Most of them began systemic medication, this was twice as common in PsA patients compared to psoriasis patients (Psoriasis: 32.11 %, PsA: 65.05 %). In this context, methotrexate (40.78%), oral glucocorticosteroids (19.42 %), and IL-17 inhibitors (9.71 %) were the most commonly prescribed medications in PsA (Figure 1 and 2). This close collaboration lead to a long-lasting remission time of musculoskeletal complaints (at least 22.5 (IQR:3.0-53.0) median months) and skin lesions (at least 22.0 (IQR:3.0-53.0) median months) in over 60 % of PsA patients (Figure 3).

Conclusion: We were able to demonstrate that close collaboration between dermatology and rheumatology can result in improved therapeutic management of psoriasis and PsA patients with a high degree of achieved clinical remission.

Sankey Chart of psoriasis patients illustrating therapeutic management over time in a specialized dermatological-rheumatological center
Therapeutic profile of psoriasis patients at time of consultation and initiated systemic therapy divided into conventional therapy, conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), targeted synthetic DMARDs (tsDMARDs), and biologic DMARDs (bDMARDs)

Sankey Chart of psoriatic arthritis patients illustrating therapeutic management over time in a specialized dermatological-rheumatological center
Therapeutic profile of psoriatic arthritis patients at time of consultation und initiated systemic therapy divided into conventional therapy, conventional synthetic DMARDs (csDMARDs), targeted synthetic DMARDs (tsDMARDs), and biologic DMARDs (bDMARDs)

Clinical remission in patients with psoriatic arthritis after consultation
Abbreviations: n = number


Disclosures: J. Ziob, None; C. Behning, None; P. Brossart, None; T. Bieber, None; D. Wilsmann-Theis, None; V. Schäfer, None.

To cite this abstract in AMA style:

Ziob J, Behning C, Brossart P, Bieber T, Wilsmann-Theis D, Schäfer V. Therapeutic Management and Clinical Remission in a Specialized Dermatological-Rheumatological Center for Patients with Psoriasis and Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/therapeutic-management-and-clinical-remission-in-a-specialized-dermatological-rheumatological-center-for-patients-with-psoriasis-and-psoriatic-arthritis/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-management-and-clinical-remission-in-a-specialized-dermatological-rheumatological-center-for-patients-with-psoriasis-and-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences